Nano-X Imaging Ltd. (NNOX)
NASDAQ:NNOX
Want to see NNOX full AI Analyst Report?
Earnings Data
Report Date
May 27, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.21Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced/Neutral — The call highlighted meaningful commercial progress: large distribution frameworks (including a 300-system Howard agreement), an expanded sales pipeline (~400 systems potential), regulatory advances, product awards, and an acquisition that immediately contributed revenue and IT capabilities. However, these operational and commercial positives are offset in the near term by significant financial headwinds: a large GAAP loss driven by a $17.5M impairment tied to a manufacturing restructuring, deteriorated non-GAAP gross margins (32% vs 9% prior), continued losses on early hardware deployments, and elevated operating expenses. Management expects a revenue inflection in the second half of 2026, but deployment timing and conversion of the pipeline into sustainable revenue remain key risks.Company Guidance
Significant Commercial Agreements and Deployment Pipeline
Signed a framework with Howard Technology Solutions expected to deploy 300 Nanox.ARC systems over 3 years (60 in year 1); management also cited multiple agreements totaling ~360 systems over 2–3 years and stated potential present/future placements up to ~400 systems globally. Approximately 38 systems are at various stages of deployment and ~15 systems are expected to be installed in the next few months — representing material pipeline depth and a shift toward more CapEx-driven placements.
Revenue Growth and Teleradiology Momentum
Total reported revenue for Q4 2025 was $3.7M, up 23% year-over-year from $3.0M. Revenue from teleradiology services rose to $3.1M from $2.8M (≈+11%), with non-GAAP teleradiology gross profit increasing to $1.5M (non-GAAP margin ≈48% vs 41% prior), driven by customer retention, higher rates and increased reading volume.
2026 Revenue Target and Ramp Expectations
Company reiterated a full-year 2026 revenue target of $35M and guided that most of the revenue ramp is expected in the second half of 2026, driven by onboarding and activation of recently signed distribution and channel agreements.
Acquisition and AI / Health IT Progress
Acquired VasoHealthcare IT (now Nanox Health IT) on Nov 19, 2025; this contributed ~$0.4M of Q4 revenue and is expected to contribute revenue from day one while improving integration into clinical workflows and lead generation for Nanox.AI. Nanox.AI advanced clinical work including a Cedars-Sinai trial (re-evaluation on ~600 retrospective cases yielding clinically relevant findings) and other validation efforts.
Regulatory and Scientific Recognition
Regulatory: TAP2D 2D output cleared in U.S.; AMAR approval updated in Israel enabling use without adjunctive limitation; CE Mark submission planned in 2026. Recognition: Red Dot Award 2026 and ECR Newcomer award — signaling improved market perception and traction at major conferences (RSNA, ECR).
Balance Sheet and Near-Term Liquidity
Cash, cash equivalents and marketable securities of approximately $60M at Dec 31, 2025 vs $55.5M at Sep 30, 2025 (≈+8%). Raised net proceeds of ≈$15.5M during Q4 from sale of ≈4.2M ordinary shares, supporting runway during restructuring and commercialization efforts.
R&D and Product Pipeline Advancements
Continued development of next-generation field-emission X-ray sources, improved emitter designs, micro-focus and multi-zone emitter work, Nanox.MDX multisource tube R&D and multiple OEM pilot engagements (including a purchase order from a leading semiconductor equipment manufacturer and ongoing Oak Ridge prototype work).
NNOX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NNOX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 20, 2026 | $2.85 | $2.15 | -24.39% |
Nov 20, 2025 | $3.03 | $3.45 | +13.86% |
Aug 12, 2025 | $4.71 | $4.46 | -5.31% |
May 22, 2025 | $5.24 | $5.24 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nano-X Imaging Ltd. (NNOX) report earnings?
Nano-X Imaging Ltd. (NNOX) is schdueled to report earning on May 27, 2026, Before Open (Confirmed).
What is Nano-X Imaging Ltd. (NNOX) earnings time?
Nano-X Imaging Ltd. (NNOX) earnings time is at May 27, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NNOX EPS forecast?
Currently, no data Available
